Treatment Outcomes for Serious Infections Caused by Methicillin-Resistant Staphylococcus aureus with Reduced Vancomycin Susceptibility
|
|
- Ashley Parker
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE Treatment Outcomes for Serious Infections Caused by Methicillin-Resistant Staphylococcus aureus with Reduced Vancomycin Susceptibility Benjamin P. Howden, 1 Peter B. Ward, 1 Patrick G. P. Charles, 1 Tony M. Korman, 2 Andrew Fuller, 3 Philipp du Cros, 3 Elizabeth A. Grabsch, 1 Sally A. Roberts, 9 Jenny Robson, 8 Kerry Read, 10 Narin Bak, 4 James Hurley, 7 Paul D. R. Johnson, 1,5 Arthur J. Morris, 9 Barrie C. Mayall, 1 and M. Lindsay Grayson 1,5,6 1 Departments of Infectious Diseases and Microbiology, Austin Health, 2 Department of Infectious Diseases, Southern Health, 3 Department of Infectious Diseases, The Alfred Hospital, 4 Western Health, 5 Department of Medicine, University of Melbourne, 6 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, and 7 Ballarat Health Services, Ballarat, and 8 Sullivan Nicolaides Pathology, Brisbane, Australia; and 9 Auckland District Health Board and 10 North Shore Hospital, Auckland, New Zealand Although infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS) have been reported from a number of countries, including Australia, the optimal therapy is unknown. We reviewed the clinical features, therapy, and outcome of 25 patients with serious infections due to SA-RVS in Australia and New Zealand. Eight patients had endocarditis, 9 had bacteremia associated with deep-seated infection, 6 had osteomyelitis or septic arthritis, and 2 had empyema. All patients had received vancomycin before the isolation of SA-RVS, and glycopeptide treatment had failed for 19 patients (76%). Twenty-one patients subsequently received active treatment, which was effective for 16 patients (76%). Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. Twelve patients received a combination of rifampicin and fusidic acid. Surgical intervention was required for 15 patients (60%). Antibiotic therapy, especially linezolid with or without rifampicin and fusidic acid, in conjunction with surgical debulking is effective therapy for the majority of patients with serious infections (including endocarditis) caused by SA-RVS. Nosocomial infections due to methicillin-resistant Staphylococcus aureus (MRSA) are an increasing problem in many parts of the world, including in Australia [1]. The therapeutic options available to treat serious infections due to MRSA are limited. The emergence of MRSA strains with reduced vancomycin susceptibility (SA-RVS) further reduces treatment options. Initially, the clinical significance of heterogeneous vancomycin Received 7 August 2003; accepted 11 October 2003; electronically published 29 January Presented in part: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003 (abstract K-1750). Reprints and correspondence: Dr. Benjamin Howden, Department of Microbiology, Austin Hospital, Locked Bag 25, Heidelberg, Victoria, Australia, 3084 (Benjamin.Howden@austin.org.au). Clinical Infectious Diseases 2004; 38: by the Infectious Diseases Society of America. All rights reserved /2004/ $15.00 intermediate S. aureus (hvisa) strains was debated, but they have now been clearly associated with glycopeptide treatment failure [2 7], as well as with higher in-hospital patient mortality rates than MRSA [8]. Serious clinical infections with SA-RVS both vancomycinintermediate S. aureus (VISA) and hvisa have now been reported in many countries, yet treatment efficacy has not been systematically assessed [9 11]. The laboratory confirmation of SA-RVS remains problematic and time-consuming, with the population analysis profile (PAP) being considered the current reference standard test [12]. After our initial report [11], we developed a protocol incorporating PAP testing for the investigation of possible SA-RVS isolates. Many isolates from across Australasia have since been referred to our department for testing. To assess the clinical features and treatment outcomes of patients with serious infections due to SA-RVS, we systematically re- Treatment of SA-RVS CID 2004:38 (15 February) 521
2 viewed data for all patients whose referred sterile site isolates were confirmed to be SA-RVS in our laboratory. PATIENTS, MATERIALS, AND METHODS Ascertainment and review of patients. All patients with a sterile site isolate confirmed as SA-RVS (see laboratory methods and susceptibility definitions below) whose isolate was referred to our laboratory during the period of 1 May 2001 through 31 January 2003 were eligible for inclusion in this study. A questionnaire was sent to the referring clinician to obtain the patient s demographic characteristics and data on comorbidities, risk factors for infection, infection, treatment, and outcome. Clinical definitions. Glycopeptide failure was defined as a blood culture positive for S. aureus after 7 days of glycopeptide therapy or as a sterile site isolate positive for S. aureus after 21 days of glycopeptide therapy. The type of infection was accepted as that reported by the treating clinician. However, a diagnosis of osteomyelitis required consistent nuclear or radiographic image (e.g., technetium bone scan or MRI) findings and/or histological confirmation, and a diagnosis of endocarditis was required to meet recognized criteria [13]. Cure was defined as no clinical or laboratory evidence of infection after the completion of antimicrobial therapy; furthermore, the patient had to be alive at follow-up. Effective suppression was defined as no clinical or laboratory evidence of active infection while receiving suppressive oral antimicrobial therapy. Effective therapy was defined as cure or effective suppression; patients who were apparently cured but who died of another cause during the follow-up period were also considered to have received effective therapy. Relapse was defined as additional sterile site isolate(s) that tested positive for SA- RVS or MRSA either after cessation of the antimicrobial therapy that had initially lead to clearance of infection or during receipt of appropriate therapy. Because patient outcomes were assessed in May 2003, the duration of follow-up varied on the basis of the date of initial diagnosis of SA-RVS infection. Laboratory methods and susceptibility definitions. The identification of all isolates as S. aureus was confirmed using standard methods [14]. The MIC of vancomycin was determined using the broth microdilution method for all isolates, in accordance with NCCLS recommendations [15], using cation-adjusted Mueller-Hinton broth. Susceptibility tests for linezolid, quinupristin-dalfopristin, and oxacillin were performed using the Etest (AB Biodisk), in accordance with the manufacturer s instructions. Testing of all other antimicrobial susceptibility was performed using agar dilution, in accordance with NCCLS criteria [15]. Population analysis profile testing and calculation of the area under the curve (AUC) of test strains and an Mu3 control (ATCC ) were performed as described elsewhere [12]. The ratio of the AUC of the test isolate to that of the Mu3 control (PAP/AUC ratio) was calculated. SA-RVS was defined as an isolate of S. aureus with a PAP/AUC ratio of 0.9 [12]. PFGE and riboprinting. Riboprint patterns were obtained using the RiboPrinter Microbial Characterisation System (Qualicon) with EcoR1 digestion. The riboprint pattern was determined using a combination of visual and computerassisted analysis. PFGE was performed on all isolates using methods described elsewhere, with some modifications [16]. For PFGE, strains were considered to be indistinguishable if there was no difference in bands, and they were considered to be related (i.e., subtypes of the same PFGE subtype) if they varied by 1 3 bands. A PFGE dendogram was constructed using GelCompar II (Applied Maths) to calculate similarity coefficients and to perform unweighted pair group analysis using arithmetic mean clustering. Dice coefficient with 0.5% optimization and 1.0% position tolerance was used. Three isolates from each of the 2 major PFGE groups found were referred to another laboratory for comparison, by PFGE analysis, with reference epidemic MRSA strains currently circulating in Australia and New Zealand. RESULTS Clinical treatment questionnaires were completed for 25 (89%) of the 28 patients who had a referred sterile site isolate confirmed to be SA-RVS at our laboratory during the study period. Patient demographics and risk factors for infection are presented in table 1. Twenty-three patients had a previously documented MRSA infection, but all 25 patients had received glycopeptide therapy at some time before the diagnosis of SA-RVS. The source of the SA-RVS infection was determined in 18 cases (surgical wound infection, 12 [67%] of 18; central intravenous line infection, 2 [11%]; diabetic foot infection, 2 [11%]; biliary stent infection, 1 [6%]; catheter related urinary tract infection, 1 [6%]). Data on 5 patients (patients 1, 2, 6, 9, 14; table 2) had been briefly reported in a previous publication by our group [17], but because this report did not include the patients treatment and outcome data, they were further described in this study. All patients had serious infections caused by SA-RVS (table 2), including 17 patients with bacteremia (endocarditis, 8 patients; osteomyelitis and/or septic arthritis, 4; intra-abdominal or biliary sepsis, 2; pacemaker abscess, 1; other, 2). Six patients had osteomyelitis and/or septic arthritis (including 3 patients with prosthetic joint infection) without bacteremia, and 2 patients had postsurgical empyema. Prolonged bacteremia while receiving vancomycin therapy was common among patients with endocarditis (median duration of bacteremia, 13 days; range, 7 32 days) and among those with osteomyelitis and/or septic arthritis (median duration of bacteremia, 9.5 days; range, 522 CID 2004:38 (15 February) Howden et al.
3 Table 1. Demographic characteristics of and risk factors for 25 patients infected with Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS). Characteristic Value Ratio of men to women 16:9 Age, median years (range) 65 (45 83) MRSA infection before SA-RVS 23 Median time from initial diagnosis of MRSA infection to SA-RVS detection (range) 22 days (3 days 31 months) Duration of glycopeptide therapy during the 6 months before SA-RVS detection, median days (range) 15 (0 91) Predose vancomycin serum level of!10 mg/ml in the first week of therapy 16 a Risk factor Diabetes 8 Immunosuppression 7 Malignancy 6 End-stage renal failure 3 Surgery!8 weeks before SA-RVS detection 18 Hospital location at time of diagnosis of SA-RVS infection ICU 9 Medical ward 7 Surgical ward 8 Outpatient 1 NOTE. Data are no. of patients, unless otherwise indicated. ICU, intensive care unit. a Data are for only 20 patients with SA-RVS infection who had vancomycin levels assessed during the first week of glycopeptide therapy days). Glycopeptide therapy failed for 19 (76%) of 25 patients, 15 of whom had detectable S. aureus bacteremia after 7 days of glycopeptide therapy, and 4 of whom had S. aureus isolated from a sterile site after 21 days of glycopeptide therapy. The PAP/AUC ratio range was , and the MIC of vancomycin (determined using the broth microdilution method) was 2 4 mg/l for all isolates (table 2). Although all isolates were susceptible to linezolid and quinupristin-dalfopristin, resistance and intermediate susceptibility were common for multiple other antibiotics, as follows: 100% of the isolates were resistant to oxacillin and to trimethoprim-sulfamethoxazole, 96% were resistant and 4% had intermediate susceptibility to tetracycline, 88% were resistant and 8% had intermediate susceptibility to erythromycin, 88% were resistant to gentamicin, 88% were resistant to ciprofloxacin, 36% were resistant to rifampicin, 8% were resistant to fusidic acid, and 4% were resistant to chloramphenicol. Notably, resistance to rifampicin developed during initial therapy for bacteremia in 3 cases (2 cases were being treated with vancomycin and rifampin, and 1 case was being treated with vancomycin, rifampicin, and fusidic acid). PFGE demonstrated 7 groups, with the majority of isolates being in 2 main groups (figure 1). There were 3 riboprint patterns, with most isolates in 2 groups. There was only limited correlation between the riboprint pattern and PFGE group. Although a number of isolates were found to be identical by PFGE, they had generally been isolated from different hospitals or at different times, indicating that cross-transmission was unlikely to be responsible for the similarities. Isolates from PFGE groups E and G were found, by comparison with reference strains, to be AUS2 and AUS3 epidemic MRSA, the most common multidrug-resistant strain of MRSA found in Australian hospitals, especially those in eastern Australia [18]. Twenty-one of the 25 patients received active antibiotic therapy to treat their SA-RVS infection, and 4 patients (patients 15, 16, 17, and 22; table 2) received either no therapy or minimal therapy directed at their SA-RVS infection. Three patients (patients 15 17) died before or soon after the SA-RVS infection was recognized. A fourth patient (patient 22) with a past history of multiple antibiotic-related adverse reactions and complications who had infected bilateral total hip prostheses was considered to have no treatment options except complete surgical removal of the infected prostheses, but this was refused by the patient. A number of antibiotic combinations were used by the 21 actively treated patients, but treatment with linezolid was most common ( n p 18), either alone ( n p 9) or sequentially with other agents, especially rifampicin and fusidic acid ( n p 8). For Treatment of SA-RVS CID 2004:38 (15 February) 523
4 Table 2. (SA-RVS). Details of disease and treatment in patients infected with Staphylococcus aureus with reduced vancomycin susceptibility Patient Age in years/sex Type (site) of infection Underlying disease or risk factor 1 80/M Endocarditis (TV) Diabetes mellitus, Wegner granulomatosis, ESRF, immunosuppression, IVC filter Duration of positive blood culture results during glycopeptide therapy, days MIC of vancomycin, a mg/l /F Endocarditis (TV), PPM, IVC filter Diabetes mellitus, IHD, PPM, recent IVC filter /M Endocarditis (MV) Retroperitoneal fibrosis, steroid therapy, recent laparotomy 4 73/F Endocarditis (TV), vertebral OM, epidural, psoas, splenic abscesses 8 2 Bowel carcinoma, steroid therapy /F Endocarditis (MV) Diabetes mellitus, cervical carcinoma, steroid therapy, aortic stenosis 6 72/M Endocarditis (prosthetic AV) Inflammatory arthritis, steroid therapy, AVR, MVR, PPM, recent open cholecystectomy 7 77/F Endocarditis (AV), splenic, renal abscess Diabetes mellitus, AS, MR, recent small bowel resection for polyps 8 67/M Endocarditis (prosthetic AV), mediastinitis 9 45/M Bacteremia, spinal OM, spinal wound infection 10 46/F Bacteremia, extensive OM (foot), stump infection 11 63/M Bacteremia, SA (knee), vertebral OM, epidural abscess Diabetes mellitus, recent AVR 32 2 Automobile accident, paraplegic, recent thoracic fusion 12 4 Diabetes mellitus, ESRF, PVD 5 2 Diabetes mellitus, recent knee reconstruction and posttrauma ORIF /M Bacteremia, SA (shoulder, THR, TKR) RA, steroid therapy, THR, TKR /F Bacteremia, intraabdominal collections PVD, recent AAA graft and small bowel resection 14 55/F Bacteremia, biliary stent, liver abscess Cholangiocarcinoma, chemotherapy, recent biliary stent 15 83/M Bacteremia, PPM abscess PPM, AVR, colonic cancer, recent hemicolectomy /F Bacteremia Diverticular disease, recent hemicolectomy /F Bacteremia, pneumonia, meningitis Removal of pituitary adenoma, CSF leak /M OM (1st metatarsal), abscess (foot) Diabetes mellitus, PVD /M SA (prosthetic knee joint) TKR /M SA, OM (shoulder) Fall, recent arthroscopy of shoulder /F OM, SA (tibia/knee) ORIF of tibial fracture /M Bilateral SA, OM (THR) Bilateral THR /M OM, SA (first MTPJ) ESRF, renal transplantation /M Empyema Dermoid tumor in chest wall, recent thoracotomy /M Empyema, pneumonia Lung cancer, recent lobectomy 4 NOTE. AAA, abdominal aortic aneurysm; AUC, area under the curve; AV, aortic valve; AVR, aortic valve replacement; CCF, congestive cardiac failure; ESRF, end-stage renal failure; IVC, inferior vena cava; MTPJ, metatarsophalyngeal joint; MV, mitral valve; OM, osteomyelitis; ORIF, open reduction internal fixation; PAP, population analysis profile; PPM, permanent pacemaker; PVD, peripheral vascular disease; SA, septic arthritis; THR, total hip replacement; TKR, total knee replacement; TV, tricuspid valve. a Determined using the broth microdilution method. cases in which linezolid was used in combination with other antibiotics, linezolid monotherapy was usually given until the infection was clinically controlled (range, days), followed by an alternative regimen (usually rifampicin with fusidic acid) either to complete a defined treatment course or for long-term suppression. One patient (patient 12; table 2) was treated with fusidic acid and chloramphenicol after initial control of the infection with linezolid, because the infection was resistant to rifampicin and all other available agents. Of note, 1 patient with osteomyelitis and septic arthritis of the first metatarso- 524 CID 2004:38 (15 February) Howden et al.
5 PAP/AUC ratio Antibiotic therapy (duration) Other interventions Treatment outcome Overall outcome Comments 1.43 Linezolid (40 days) None Effective therapy Cured Follow-up duration of 10 months 1.14 Rifampin plus fusidic acid (11 days), then linezolid (38 days) TV vegetectomy, removal of PPM and IVC filter Effective therapy Cured Follow-up duration of 10 weeks 1.01 Linezolid (49 days) None Effective therapy Cured Follow-up duration of 3 months 1.77 Linezolid (42 days), then rifampin plus fusidic acid (8 days) 1.40 Linezolid plus rifampin and fusidic acid (12 days) 0.91 Rifampin plus fusidic acid (12 days) 1.14 Rifampin (9 days), then linezolid (7 days) 0.90 Linezolid (42 days) Redo AVR with homograft 10 days after linezolid therapy was stopped 1.36 Linezolid (32 days), then rifampin plus fusidic acid to suppression None Effective therapy Died Died of comorbidities; culture results were negative after linezolid therapy MV repair Not effective Died Died of cardiac failure; culture results were negative after linezolid therapy None Not effective Died Active therapy ceased after cerebral embolus None Not effective Died Died of severe sepsis, CCF; culture results were positive after linezolid therapy Laminectomy, wound debridement Not effective Died Died of postoperative bleeding; further positive blood culture results after linezolid therapy was ceased Effective suppression Clinically Follow-up duration of 10 months healthy 0.95 Linezolid (60 days) Above-knee amputation Effective therapy Cured Follow-up duration of 1 month 1.34 Rifampin plus fusidic acid (10 months) to suppression 0.93 Linezolid (31 days), then fusidic acid and chloramphenicol long term 1.12 Linezolid (17 days), then rifampin plus fusidic acid (14 days) 1.17 Linezolid (34 days), then rifampin plus fusidic acid (14 days) Multiple washouts, cervical and tho-racic laminectomies Effective suppression Clinically healthy None Relapse Clinically healthy Follow-up duration of 7 months Relapse of SA-RVS bacteremia while receiving fusidic acid and chloramphenicol; resolved None Effective therapy Died Died of bacteremia due to gram-negative organisms; no further SA-RVS detected Multiple drainages Effective therapy Died Died of cancer; no further SA-RVS detected 1.38 Rifampin plus fusidic acid (1 day) PPM explanted N/A Died Died of overwhelming sepsis 1.87 None None N/A Died Died of overwhelming sepsis 0.93 None None N/A Died Died of overwhelming sepsis 0.95 Linezolid (42 days) Abscess drainage Effective therapy Cured Follow-up duration of 4 months 1.22 Linezolid (78 days), then rifampin plus fusidic acid Removal of prosthetic knee Effective suppression Clinically healthy Received suppressive therapy; followup duration of 10 months 1.15 Linezolid (63 days) Shoulder washout Effective therapy Cured Follow-up duration of 5 months 1.10 Linezolid (28 days) Removal of plates and screws Effective therapy Cured Follow-up duration of 69 days 1.14 None Removal of THR N/A Chronic Chronic low-grade infection of left THR infected 0.91 Vancomycin (77 days) None Effective therapy Cured Follow-up duration of 6 months 1.28 Linezolid (56 days) Drainage of empyema Effective therapy Cured Follow-up duration of 2 weeks 1.07 Linezolid (42 days) Decortication Effective therapy Cured Follow-up duration of 4 months phalangeal joint (patient 23; table 2) was treated (and cured) with 11 weeks of vancomycin therapy because the managing clinicians were unaware that the infection was due to SA-RVS. Although this isolate fulfilled the definition of SA-RVS (PAP/ AUC ratio, 0.91), the clinical course was such that no additional isolates were recovered for testing. In the actively treated group ( n p 21), 16 patients (76%) had an effective response to therapy. Ten patients (48%; patients 1 3, 10, 18, 20, 21, and 23 25) were cured at follow-up (table 2), 3 (14%; patients 9, 11, and 19) received effective suppressive therapy (table 2), and an additional 3 (14%; patients 4, 13, and 14), although they were apparently cured of infection, had died Treatment of SA-RVS CID 2004:38 (15 February) 525
6 Figure 1. PFGE analysis of 25 Staphylococcus aureus isolates with reduced vancomycin susceptibility. A, Alfred Hospital (Australia); B, Ballarat Health Services (Australia); M, Monash Medical Centre (Australia); N, Auckland District Health Board (New Zealand); O, North Shore Hospital (New Zealand); Q, Sullivan Nicolaides Pathology (Australia); R, Royal Melbourne Hospital (Australia); U, Austin Health (Australia); W, Western Hospital (Australia). of their underlying diseases at the time of follow-up (table 2). The length of follow-up for these effectively treated patients is described in table 2. SA-RVS infection clearly contributed to the death of an additional 4 patients. Thus, 7 patients (33%) had died at follow-up. The sole patient who experienced relapse (patient 12; table 2) had a good response to linezolid for multifocal prosthetic joint septic arthritis, but his clinical condition deteriorated, with a single additional blood culture positive for MRSA 4 months after treatment was changed to long-term suppressive therapy with fusidic acid and chloramphenicol. Despite the fact that the patient remained on fusidic acid and chloramphenicol, the results of 4 additional sets of blood cultures were negative, and the patient eventually stabilized. He was clinically healthy 2 months later while receiving suppressive therapy. Among the 18 patients who received linezolid therapy, the duration of linezolid treatment varied (range, 7 78 days) but was generally prolonged (median, 41 days). Side effects while receiving linezolid occurred in 8 patients and included thrombocytopenia ( n p 5), abnormal liver function test values ( n p 1), nausea ( n p 1), and taste disturbance ( n p 1). In 3 patients, the platelet count decreased to! platelets/l, with 1 patient requiring a platelet transfusion. All 3 patients had endocarditis and developed thrombocytopenia after 35 days of therapy. Two patients (patients 2 and 4; table 2) completed their course of linezolid therapy despite having platelet 9 9 counts of and platelets/l, respectively, with no further decrease in the platelet count. One patient (patient 1; table 2), whose platelet count decreased to platelets/ L, stopped taking linezolid therapy 2 days early, and no alternate therapy was used. The other 2 patients who developed mild thrombocytopenia continued to receive linezolid therapy. Surgery was an important component of therapy for 13 patients in the actively treated group, including 69% of patients for whom therapy was effective. Of the 13 actively treated patients who underwent surgery, 11 (85%) received effective therapy, whereas, of those who did not undergo surgery, 5 (63%) of 8 received effective therapy. The surgery usually involved significant debulking of infection (e.g., vegetectomy, debridement and removal of infected prosthetic devices, and drainage of multiple liver abscesses), and, in some cases, repeated surgery was required. DISCUSSION We found that serious infections due to SA-RVS in Australasia were generally identified in patients in whom glycopeptide treatment had failed. This correlates with previous reports of treatment failure in patients infected with these SA-RVS strains [4, 7, 8]. Nevertheless, the vast majority of these patients were 526 CID 2004:38 (15 February) Howden et al.
7 effectively treated with antibiotics, either alone (31%) or in combination with surgical debulking of the infected site (69%). Linezolid was the most commonly used antibiotic, particularly for initial therapy, followed, in some patients ( n p 5), by a switch to combination therapy with rifampicin and fusidic acid. Overall, adverse reactions were uncommon, except for thrombocytopenia in patients receiving prolonged courses of linezolid. These results are encouraging, given the serious nature of the infections we observed and the high rate of complex comorbidities in these patients. In particular, our relative success in treating endocarditis due to SA-RVS (therapy was effective for 4 of 8 patients) is notable, given that there is only a single previous reported case of successful treatment of SA- RVS endocarditis [19]. However, the fact that the remaining 4 patients with endocarditis died of complications (2 had ongoing bacteremia, despite receiving linezolid therapy) highlights the difficulties associated with this disease. Overall, in our study, linezolid appeared to be a relatively safe and effective agent, as long as therapy was not prolonged. All patients in this study had a clinical course that was consistent with infection with a staphylococcal strain that had reduced susceptibility to vancomycin. Nevertheless, these isolates highlighted the difficulty in readily detecting such vancomycin resistance in vitro, given that all strains initially demonstrated an MIC of vancomycin in the susceptible range ( 4 mg/l), with a number of strains ( n p 15) having an MIC of vanco- mycin of only 2 mg/l. Thus, studies that use the criteria of an MIC of vancomycin of 4 mg/l or growth on media containing vancomycin, 4 mg/l, as diagnostic for SA-RVS [8, 20] may overlook such strains as ours and not proceed to PAP testing. However, as 1 patient (patient 23) in our study demonstrated, even PAP findings do not always correlate with clinical outcome. The SA-RVS strain isolated from patient 23 had a PAP/AUC ratio of 0.91 (i.e., just above the cutoff for SA- RVS) and an MIC of vancomycin of 2 mg/l (as determined using the broth microdilution method), yet the infection was apparently eradicated and the patient cured after receiving an 11-week treatment course of vancomycin. There are a number of potential explanations for the outcome in this case. First, given that the patient had end-stage renal failure and reduced vancomycin clearance, serum and bone vancomycin concentrations may have been substantially higher than in patients with more normal renal function. Second, the proportion of this patient s S. aureus population with reduced susceptibility to vancomycin may have been sufficiently low that the combination of high vancomycin levels and the patient s routine immune function may have been sufficient to eradicate resistant subpopulations. The mechanisms of vancomycin resistance in S. aureus are not known, although a thickened cell wall is a common feature, and this appears to be inducible by vancomycin [10, 21]. Consistent with this observation, most of our patients not only had previous MRSA infection and glycopeptide exposure, but 80% of those with recorded vancomycin levels had a low (!10 mg/ L) trough concentration during the first week of vancomycin therapy. Low vancomycin levels, particularly in the early stages of therapy, could result in induction of preexisting low-level vancomycin resistance or could select for new vancomycinresistant strains [10]. This clearly has implications in terms of the emphasis placed on surgical drainage and debulking of high bacterial load infections in such patients (e.g., MRSAassociated abscesses and infected prostheses) and possibly has implications on vancomycin dosing. Whenever possible, MRSA-associated abscesses should be drained and a high priority given to removal of infected prosthetic devices. Molecular assessment of our SA-RVS isolates indicated a number of PFGE groups, with no substantive evidence of clonal dissemination. Isolates that appeared to be clonal were generally not epidemiologically linked either by institution or time. Nevertheless, the fact that PFGE analysis suggested that some strains were closely related to the AUS2 and AUS3 MRSA strains that are the most common multidrug-resistant MRSA strains found in Australia [18] is concerning and highlights the potential for MRSA strains with reduced susceptibility to vancomycin to become widespread in Australia. Our study has some limitations. First, it is not possible, given the methodology of our case detection, to identify the correct clinical sequence in our patients namely, whether our patients infections were ineffectively treated with glycopeptides with reduced susceptibility to vancomycin, thereby being induced and resulting in greater glycopeptide failure; or whether SA-RVS strains were primarily responsible for the infection all along, and glycopeptide failure was an inevitable consequence. Second, given the size and descriptive nature of our study, we cannot be certain about the efficacy of agents such as linezolid and rifampicin plus fusidic acid. However, our results are encouraging, especially if a combined medical and surgical approach is taken. Our study suggests that SA-RVS is not just a laboratory phenomenon, but that such strains are associated with serious infections that respond to carefully targeted nonglycopeptide therapy. With the increasing recognition of SA-RVS, future controlled studies comparing the efficacy of therapeutic agents should be performed. Acknowledgment We thank Geoff Coombs (Royal Perth Hospital; Perth, Australia), for performing PFGE typing of selected isolates, and the Treatment of SA-RVS CID 2004:38 (15 February) 527
8 microbiology and clinical staff from each of the hospitals that contributed cases. References 1. Turnidge JD, Nimmo GR, Francis G. Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Med J Aust 1996; 164: Turner J, Howe RA, Wootton M, et al. The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model. J Antimicrob Chemother 2001; 48: Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: Geisel R, Schmitz FJ, Thomas L, et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 1999; 43: Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, Clin Infect Dis 2003; 36: Hiramatsu, K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: Ward PB, Johnson PD, Grabsch EA, Mayall BC, Grayson ML. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 2001; 175: Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect heteroresistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: Kloos WE, Banerman TL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 7th ed. Washington, DC: American Society for Microbiology Press, 1999: NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A5. Wayne, PA: NCCLS, Murchan S, Kaufmann ME, Deplano A, et al. Harmonization of pulsedfield gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol 2003; 41: Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: Coombs GW, Malkowski MJ, Pearson JC, Bell JM, Nimmo GR. Epidemic MRSA in Australia [abstract ]. Australian Group for Antimicrobial Resistance. In: Program and abstracts of the 10th International Symposium on Staphylococci and Staphylococcal Infections, Japan. Tokyo: Japanese Association for Infectious Diseases, 2002: Andrade-Baiocchi S, Tognim MC, Baiocchi OC, Sader HS. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn Microbiol Infect Dis 2003; 45: Schwaber MJ, Wright SB, Carmeli Y, et al. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 2003; 9: Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002; 15: CID 2004:38 (15 February) Howden et al.
Received 10 October 2008/Returned for modification 15 March 2009/Accepted 1 June 2009
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2009, p. 3447 3452 Vol. 53, No. 8 0066-4804/09/$08.00 0 doi:10.1128/aac.01365-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Prospective
More informationReceived 24 August 2010/Returned for modification 7 November 2010/Accepted 7 February 2011
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1583 1587 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.01719-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Clinical and
More informationThe first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland
Journal of Antimicrobial Chemotherapy (2002) 50, 1065 1069 DOI: 10.1093/jac/dkf252 The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland Jolanta Krzysztoá-Russjan
More informationClinical Failure of Vancomycin Treatment of Staphylococcus aureus Infection in a Tertiary Care Hospital in Southern Brazil
224 BJID 2003; 7 (June) Clinical Failure of Vancomycin Treatment of Staphylococcus aureus Infection in a Tertiary Care Hospital in Southern Brazil Larissa Lutz, Adão Machado, Nadia Kuplich and Afonso Luís
More informationPerformance of Various Testing Methodologies for Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus in Bloodstream Isolates
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1489 1494 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.02302-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Performance
More informationPATIENT DEMOGRAPHICS. Surname. Given name. Pacific Islander (non-maori) ADMISSION DETAILS
Reviewer / hospital Date review started PATIENT DEMOGRAPHICS MRN DOB Sex Patient sticky label if available, else enter details here Surname Post-code Given name Australian Aborigine / TSI Middle Eastern
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationThe relationship between hvisa, VISA, high vancomycin MIC and outcome in
JCM Accepts, published online ahead of print on 16 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00775-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 The relationship between
More informationThe Challenge of Managing Staphylococcus aureus Bacteremia
The Challenge of Managing Staphylococcus aureus Bacteremia M A R G A R E T G R A Y B S P F C S H P C L I N I C A L P R A C T I C E M A N A G E R N O R T H / I D P H A R M A C I S T A L B E R T A H E A
More informationSpectrum of vancomycin and susceptibility testing
Spectrum of vancomycin and susceptibility testing Olivier Denis Service de Microbiologie Laboratoire de bactériologie Service de Microbiologie Hôpital Erasme Glycopeptides Vancomycin 1958 < Amycolatopsis
More informationValidation of Vitek version 7.01 software for testing staphylococci against vancomycin
Diagnostic Microbiology and Infectious Disease 43 (2002) 135 140 www.elsevier.com/locate/diagmicrobio Validation of Vitek version 7.01 software for testing staphylococci against vancomycin P.M. Raney a,
More informationRelationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2004, p. 2398 2402 Vol. 42, No. 6 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.6.2398 2402.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationAn evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus
Asian Biomedicine Vol. 4 No. 1 February 2010; 141-145 Brief communication (Original) An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus
More informationThe Presence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (heterovisa) in a Major Malaysian Hospital
ORIGINAL ARTICLE The Presence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (heterovisa) in a Major Malaysian Hospital Norazah Ahmad, MD, MSc, PhD*, Law Ngiik Ling, BSc**, Mohamed Kamel
More informationInfections Amenable to OPAT. (Nabin Shrestha + Ajay Mathur)
3 Infections Amenable to OPAT (Nabin Shrestha + Ajay Mathur) Decisions regarding outpatient treatment of infections vary with the institution, the prescribing physician, the individual patient s condition
More informationVancomycin: Class: Antibiotic.
Vancomycin: Class: Antibiotic. Indications: Treatment of patients with infections caused by staphylococcal species and streptococcal Species. Available dosage form in the hospital: 1G VIAL, 500MG VIAL.
More informationReceived 26 March 2008/Returned for modification 5 May 2008/Accepted 9 July 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2008, p. 2950 2954 Vol. 46, No. 9 0095-1137/08/$08.00 0 doi:10.1128/jcm.00582-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Characterization
More informationINFECTION & INFLAMMATION IMAGING
INFECTION & INFLAMMATION IMAGING Radiopharmaceutical Drug Interactions & Other Interesting Case Studies MICHELLE RUNDIO, CNMT NCT MBA PCI NUCLEAR IN-111 WHITE BLOOD CELL IMAGING Interactions, Imaging Parameters
More informationVancomycin resistance in Staphylococcus aureus
INTERNATIONAL NEWSLETTER no 3 SEPTEMBER 2002 STATE-OF-THE-ART THE BIOMERIEUX SOLUTION DID YOU KNOW? PRACTICAL ADVICE Vancomycin resistance in Staphylococcus aureus VITEK 2 performance Web site 10 th ISSSI
More informationTreatment of infection
Clinica Ortopedica e Traumatologica Università degli Studi di Pavia Fondazione IRCCS Policlinico San Matteo Chairman: Prof. F. Benazzo Goals: - Healing of infection - Healing of fracture - Try to keep
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationInfected cardiac-implantable electronic devices: diagnosis, and treatment
Infected cardiac-implantable electronic devices: diagnosis, and treatment The incidence of infection following implantation of cardiac implantable electronic devices (CIEDs) is increasing at a faster rate
More informationEffects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia
Journal of Antimicrobial Chemotherapy (2006) 57, 699 704 doi:10.1093/jac/dkl030 Advance Access publication 7 February 2006 Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus
More informationMichael S. Niederman, M.D. Clinical Director Pulmonary and Critical Care Medicine New York Presbyterian Hospital Weill Cornell Medical Center
CA-MRSA Pneumonia Michael S. Niederman, M.D. Clinical Director Pulmonary and Critical Care Medicine New York Presbyterian Hospital Weill Cornell Medical Center Professor of Clinical Medicine Weill Cornell
More informationBacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis
Journal of Antimicrobial Chemotherapy (2003) 52, 820 825 DOI: 10.1093/jac/dkg440 Advance Access publication 30 September 2003 Bacteriological outcome of versus single-agent treatment for staphylococcal
More informationClinical Implications of Vancomycin Heteroresistant and Intermediately Susceptible Staphylococcus aureus
University of Rhode Island DigitalCommons@URI Pharmacy Practice Faculty Publications Pharmacy Practice 2015 Clinical Implications of Vancomycin Heteroresistant and Intermediately Susceptible Staphylococcus
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationHospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia
Hospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia Amanda Guth 1 Amy Slenker MD 1,2 1 Department of Infectious Diseases, Lehigh Valley Health Network
More informationClinical Significance of Varying Degrees of Vancomycin Susceptilibity. in Methicillin-Resistant Staphylococcus aureus Bacteremia1.
Clinical Significance of Varying Degrees of Vancomycin Susceptilibity in Methicillin-Resistant Staphylococcus aureus Bacteremia The Harvard community has made this article openly available. Please share
More informationTreatment of serious Pseudomonas infections with azlocillin
Journal of Antimicrobial Chemotherapy (983), Suppl. B, 53-58 Treatment of serious Pseudomonas infections with azlocillin S. Olive, W. J. Mogabgab, B. Holmes, B. Pollock, B. Pauling and R. Beville Tulane
More informationRight-Sided Bacterial Endocarditis
New Concepts in the Treatment of the Uncontrollable Infection Agustin Arbulu, M.D., Ali Kafi, M.D., Norman W. Thorns, M.D., and Robert F. Wilson, M.D. ABSTRACT Our experience with 25 patients with right-sided
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationStaphylococcal Bacteremia
Staphylococcal Bacteremia Henry F. Chambers, M.D. Professor of Medicine, UCSF Chief of Infectious Diseases San Francisco General Hospital Case 1 38 y/o man, new CHF, alcoholic cardiomyopathy, Hct = 13
More informationInvasive Staphylococcal Infections
Invasive Staphylococcal Infections Henry F. Chambers, M.D. Professor of Medicine, UCSF San Francisco General Hospital Disclosures AstraZeneca advisory board Cubist research grant, advisory panel Genentech
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More information6-8 November EICC, Edinburgh. Registration now open Abstract submission deadline: June 24th
6-8 November EICC, Edinburgh Registration now open Abstract submission deadline: June 24th An outbreak of prosthetic valve endocarditis Dr Tim Boswell Consultant Medical Microbiologist Nottingham Case
More informationInfective Endocarditis Empirical therapy Antibiotic Guidelines. Contents
Infective Endocarditis Empirical therapy Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Group Additional author(s): as above Authors Division: Division of Clinical
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationthe American College of Physicians Journal Club were searched from inception through April 2014.
Research Original Investigation Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients With Staphylococcus aureus Bloodstream Infections A Systematic Review and Meta-analysis
More informationRenal Unit. Catheter Related Bacteraemia Guidelines
Renal Unit Policy Manager Drew Henderson Policy Group Renal Unit Policy Established 21/01/2014 Policy Review Period/Expiry 21/01/2015 Last Updated 21/01/2014 This policy does apply to Medical/Dental Staff
More informationReceived 2 October 2002/Returned for modification 29 November 2002/Accepted 7 January 2003
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2003, p. 1687 1693 Vol. 41, No. 4 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.4.1687 1693.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationDaniel C. DeSimone, MD Assistant Professor of Medicine
Daniel C. DeSimone, MD Assistant Professor of Medicine Faculty photo will be placed here Desimone.Daniel@mayo.edu 2015 MFMER 3543652-1 Infective Endocarditis Mayo School of Continuous Professional Development
More informationClinical and Molecular Characteristics of Community- Acquired Methicillin-Resistant Staphylococcus Aureus Infections In Chinese Neonates
Clinical and Molecular Characteristics of Community- Acquired Methicillin-Resistant Staphylococcus Aureus Infections In Chinese Neonates Xuzhuang Shen Beijing Children's Hospital, Capital Medical University,
More informationEndocardite infectieuse
Endocardite infectieuse 1. Raccourcir le traitement: jusqu où? 2. Proposer un traitement ambulatoire: à partir de quand? Endocardite infectieuse A B 90 P = 0.014 20 P = 0.0005 % infective endocarditis
More informationORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun
ORIGINAL ARTICLE CLINICAL ASSESSMENT OF NEPHROTOXICITY ASSOCIATED WITH VANCOMYCIN TROUGH CONCENTRATIONS DURING TREATMENT OF DEEP-SEATED INFECTIONS: A RETROSPECTIVE ANALYSIS Anand Kumar Singh 1, Poonam
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationReceived 26 March 2013; returned 21 April 2013; revised 22 July 2013; accepted 26 July 2013
J Antimicrob Chemother 2014; 69: 211 218 doi:10.1093/jac/dkt340 Advance Access publication 29 August 2013 Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients
More informationMichael Stander, Pharm.D.
Michael Stander, Pharm.D. Endocarditis: Goals Epidemiology Presentation of acute and subacute. Diagnosis: What is Dukes Criteria and how do we approach the diagnosis of endocarditis? Treatment: Understand
More informationNew guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. D. C. Shanson
Journal of Antimicrobial Chemotherapy (1998) 42, 292 296 New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis JAC D. C. Shanson Microbiology Department,
More informationORIGINAL ARTICLE /j x. Melbourne, Victoria, Australia
ORIGINAL ARTICLE 10.1111/j.1469-0691.2007.01691.x Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid C. A. Aboltins 1, M.
More informationImpact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia
Journal of Microbiology, Immunology and Infection (2012) 45, 214e220 Available online at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Impact of vancomycin MIC creep on patients
More informationWhat s new in Infectious Diseases. Petronella Adomako, MD Infectious Disease Specialist Mckay-Dee Hospital
What s new in Infectious Diseases Petronella Adomako, MD Infectious Disease Specialist Mckay-Dee Hospital None Disclosures Objectives New information in infectious diseases. New diseases and outbreaks.
More informationThe EM Educator Series
The EM Educator Series The EM Educator Series: Why is my patient with gallbladder pathology so sick? Author: Alex Koyfman, MD (@EMHighAK) // Edited by: Brit Long, MD (@long_brit) and Manpreet Singh, MD
More informationAbstract. Introduction
ORIGINAL ARTICLE Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kang D-H, Kim Y-J, Kim S-H, et al. Early surgery versus conventional
More informationA Norazah, S M Liew, A G M Kamel, Y T Koh, V K E Lim. O r i g i n a l A r t i c l e
Singapore Med J 2001 Vol 42(1) : 015-019 O r i g i n a l A r t i c l e DNA Fingerprinting of Methicillin-Resistant Staphylococcus Aureus by Pulsed-Field Gel Electrophoresis (PFGE): Comparison of Strains
More informationDevelopment of bacterial resistance to antimicrobial botanical extracts
Development of bacterial resistance to antimicrobial botanical extracts Linda M. Sparks, Heather Harrington, Robert Waters, Yvan Rochon, Jeffrey Langland Arizona State University, Biodesign Institute,
More informationClinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections
REVIEWS OF INFECTIOUS DISEASES. VOL. 4, SUPPLEMENT. SEPTEMBER-OCTOBER 982 982 by The University of Chicago. All rights reserved. 062-0886/82/0405-022$02.00 Clinical Comparison of with Gentamicin plus Clindamycin
More informationLoyola ecommons. Loyola University Chicago. Virginia Long Loyola University Chicago. Recommended Citation
Loyola University Chicago Loyola ecommons Master's Theses Theses and Dissertations 2014 Identification of Clinical Markers That Predict the Outcomes of Methicillin-Resistant Staphylococcus Aureus Infections
More informationOSTEOMYELITIS. If it occurs in adults, then the axial skeleton is the usual site.
OSTEOMYELITIS Introduction Osteomyelitis is an acute or chronic inflammatory process of the bone and its structures secondary to infection with pyogenic organisms. Pathophysiology Osteomyelitis may be
More informationHeart on Fire: Infective Endocarditis. Objectives. Disclosure 8/27/2018. Mary McGreal DNP, RN, ANP-c, CCRN
Heart on Fire: Infective Endocarditis Mary McGreal DNP, RN, ANP-c, CCRN Objectives Discuss the incidence of infective endocarditis? Discuss the pathogenesis of infective endocarditis? Discuss clinical
More informationOsteomyelitis Samir S. Shah, MD, MSCE
Osteomyelitis Samir S. Shah, MD, MSCE Professor, Department of Pediatrics University of Cincinnati College of Medicine Director, Division of Hospital Medicine Attending Physician in Infectious Diseases
More informationESCMID Online Lecture Library. by author
Microbiology for implant related infections Hui Wang M.D, Professor, Director Department of Clinical Laboratory Peking University People s Hospital Beijing, 100044 Email: wanghui@pkuph.edu.cn Outline Epidemiology
More informationSepsis and Infective Endocarditis
Sepsis and Infective Endocarditis Michal Holub Department of Infectious Diseases First Faculty of Medicine Charles University in Prague and University Military Hospital Bacteremia and Sepsis bacteremia
More informationInvasive Bacterial Disease
Invasive Bacterial Disease All Streptococcus pneumoniae Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology Program : 304-558-5358 or 800-423-1271
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationIn Vitro Susceptibility of Staphylococci and Enterococci to Vancomycin and Teicoplanin
In Vitro Susceptibility of Staphylococci and Enterococci to Vancomycin and Teicoplanin 19 A. Guzek, K. Korzeniewski, Aneta Nitsch-Osuch, Z. Rybicki, and E. Prokop Abstract Hospital-acquired infections
More informationIn Vitro Susceptibilities of Aerobic and Facultative Non-Spore- Forming Gram-Positive Bacilli to HMR 3647 (RU 66647) and 14 Other Antimicrobials
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1028 1033 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Susceptibilities of Aerobic and Facultative
More informationBlood cultures in ED. Dr Sebastian Chang MBBS FACEM
Blood cultures in ED Dr Sebastian Chang MBBS FACEM Why do we care about blood cultures? blood cultures are the most direct method for detecting bacteraemia in patients a positive blood culture: 1. can
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationManagement of severe staphylococcal infections
Management of severe staphylococcal infections Dilip Nathwani BSAC April 7 th 2009 Ninewells Hospital & Medical School Dundee DD1 9SY Objectives Mortality related to MSSA and MRSA infections Glycopeptides
More informationClinical management of Staphylococcus aureus bacteremia an updated proposal of protocol
Clinical management of Staphylococcus aureus bacteremia an updated proposal of protocol Promotor : Prof. dr. W. Peetermans Second reader : Prof. dr. E. Van Wijngaerden Master s Thesis Internal Medicine
More informationAn Audit of Staphylococcus aureus Bacteraemia Treatment in a UK District General Hospital
JMID/ 2017; 7 (4):188-193 Journal of Microbiology and Infectious Diseases doi: 10.5799/jmid.369266 RESEARCH ARTICLE An Audit of Staphylococcus aureus Bacteraemia Treatment in a UK District General Hospital
More informationSteven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2063 2069 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.01569-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More informationResponders as percent of overall members in each category: Region: New England 50 (58% of 86 members) 19 (51% of 37 members) 3 (33% of 9 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Prosthetic Joint Infections (PJI) in Adults Overall response rate: 556/118 (4.2%) physicians responded from 5/16/12
More informationCharacterization of community and hospital Staphylococcus aureus isolates in Southampton, UK
Journal of Medical Microbiology (2010), 59, 1084 1088 DOI 10.1099/jmm.0.018986-0 Characterization of community and hospital Staphylococcus aureus isolates in Southampton, UK S. M. Green, 1 P. Marsh, 1
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationFrequency of Nasal Carriage of Staphylococcus Aureus and Its Antimicrobial Resistance Pattern in Patients on Hemodialysis
Dialysis Frequency of Nasal Carriage of Staphylococcus Aureus and Its Antimicrobial Resistance Pattern in Patients on Hemodialysis Roya Ghasemian, 1 Narges Najafi, 1 Atieh Makhlough, 2 Mohammad Khademloo
More informationOsteomieliti STEOMIE
OsteomielitiSTEOMIE Osteomyelitis is the inflammation of bone caused by pyogenic organisms. Major sources of infection: - haematogenous spread - tracking from adjacent foci of infection - direct inoculation
More informationD DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.
Journal of Pharmacy and Pharmacology 2 (2014) 713-721 doi: 10.17265/2328-2150/2014.12.004 D DAVID PUBLISHING Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within
More informationDr Babak Tamizi far MD. Assistant Professor Of Internal Medicine Al-Zahra Hospital Isfahan University Of Medical Sciences
Dr Babak Tamizi far MD. Assistant Professor Of Internal Medicine Al-Zahra Hospital Isfahan University Of Medical Sciences ١ ٢ ٣ A 57-year-old man presents with new-onset fever, shortness of breath, lower
More informationSuperhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia
Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia Brandon Dionne, PharmD, BCPS, AAHIVP Assistant Clinical Professor Northeastern University Seth Housman, PharmD, MPA Clinical Assistant
More informationOPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY. BSAC OPAT REGIONAL WORKSHOP London 14 May 2018
OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY BSAC OPAT REGIONAL WORKSHOP London 14 May 2018 Presented by Felicity Drummond Senior Project Manager, BSAC NORS provides the most
More informationEfficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae Strains in a rabbit meningitis model.
AAC Accepts, published online ahead of print on 3 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00285-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 1 2 Efficacy
More informationASHP Therapeutic Position Statements 623
ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society
More informationNuclear medicine and Prosthetic Joint Infections
Nuclear medicine and Prosthetic Joint Infections Christophe Van de Wiele, M.D., Ph.D. Department of Nuclear Medicine, University Hospital Ghent, Belgium Orthopedic prostheses: world market 1996 Prosthetic
More informationThe prevalence of multidrug resistance in gram-positive
Early Switch From Vancomycin to Oral Linezolid for Treatment of Gram-Positive Heart Valve Endocarditis Andrea Colli, MD, Riccardo Campodonico, MD, and Tiziano Gherli, MD Department of Cardiac Surgery,
More informationACCEPTED 1, 3, 4 * AP-HP, Hôpital Européen Georges Pompidou, Service de Microbiologie 1 and Service de
JCM Accepts, published online ahead of print on 3 December 2008 J. Clin. Microbiol. doi:10.1128/jcm.00707-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationSancak et al. BMC Infectious Diseases 2013, 13:583
Sancak et al. BMC Infectious Diseases 2013, 13:583 RESEARCH ARTICLE Open Access Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationESPID New Bone and Joint Infection Guidelines
ESPID New Bone and Joint Infection Guidelines Theoklis Zaoutis, MD, MSCE Professor of Pediatrics and Epidemiology Perelman School of Medicine at the University of Pennsylvania Chief, Division of Infectious
More informationProsthetic Valve Infective Endocarditis. Tat Yam Department of Infection Southampton University Hospitals NHS TRust
Prosthetic Valve Infective Endocarditis Tat Yam Department of Infection Southampton University Hospitals NHS TRust Case History: Episode 1 in MB 73 yr old male, Nigerian PMHx: Hypertension Congestive cardiac
More informationThe continued expansion of the geriatric population has
BRIEF REPORTS Staphylococcus aureus Bloodstream Infections in Older Adults: Clinical Outcomes and Risk Factors for In-Hospital Mortality Cecilia Big, MD, and Preeti N. Malani, MD, MSJ wz OBJECTIVES: To
More informationAntibiotic Management of Pediatric Osteomyelitis
Reprinted from www.antimicrobe.org Sandra Arnold, M.D. Antibiotic Management of Pediatric Osteomyelitis Several points uncertainty exist regarding the antimicrobial management of acute hematogenous osteomyelitis,
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationLong Term Follow-up. 6 Month 1 Year Annual enter year #: What is the assessment date: / / Unknown. Is the patient alive? Yes No
Long Term Follow-up 6 Month 1 Year Annual enter year #: What is the assessment date: / / Unknown Is the patient alive? Yes No Was an exam performed by a bariatric physician or PA/NP? Yes No Was the patient
More information